Fluorescence with ICG in sarcoma surgery
Recruiting
Who can enter
Children with a newly diagnosed tumor of the bones or soft tissue, or in whom the disease has returned (recurrence)
Children and adolescents undergoing surgery at the Princess Máxima Center for bone or soft tissue tumors
Goal
Goal
We are studying whether using ICG is helpful for all types of sarcomas in children. The fluorescent agent ICG can assist the surgeon in making the tumor visible during surgery. The goal of this study is to see how much light ICG emits in different sarcomas. After the surgery, the diseased cells that have been removed will be examined in the laboratory. We look at which parts of the tumor emit light.
Background
Background
How much light the tumor emits when using the fluorescent agent ICG is different for each patient and tumor type. Because of this, the usefulness of ICG in helping the surgeon see the tumor may vary. We assume that ICG is influenced by the type of sarcoma, or by chemotherapy or radiation before surgery.
In this study, the diseased cells that have been removed during surgery will be examined in the laboratory. Researchers and a pathologist use a microscope to find which parts of the diseased cells have ICG. They will check if ICG is present in living or dead tumor cells. The researchers will also compare this with the amount of light ICG emitted during surgery.
The patient will not need to do anything extra for this study. The diseased cells that have been removed, will be investigated in the laboratory. Therefore, there is no extra risk or burden for the patient.
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
Last reviewed
March 20, 2026
Study details
- Study details
Official title
Prospective evaluation of the correlation between histopathology and indocyanine green fluorescence in pediatric bone and soft tissue sarcomasCancer type
Bone and soft tissue tumors (sarcomas)Maximum number of patients
Approximately 100 patients with bone and/or soft tissue tumors are expected to participate in this studyStart date
November 18, 2024Status
Open for participationLocal principal investigator
Prof. Dr. M.A.J. van de SandeSponsor
Princess Máxima Center for pediatric oncologyApproval
This study has been reviewed and approved by the internal scientific committee (Clinical Research Committee) of the Princess Máxima Center. An accredited medical research ethics committee waived the need for official approval according to the Medical Research Involving Human Subjects Act (WMO), and is therefore not further involved in the review of the research. This is only done for studies with low risk or low patient burden. More information can be found at: CCMO.
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.